Janssen-cilag Ltd.

This study is observing how well the drug guselkumab works for adults with moderate-to-severe Crohn's disease or ulcerative colitis in real-world UK clinics. It will track 220 patients to see if the treatment reduces symptoms, improves quality of life, and helps them stop using s…

This study is testing whether the drug guselkumab can heal all layers of the intestinal wall in people with active Crohn's disease. It will enroll about 112 participants who have not responded well to other treatments. Doctors will use MRI scans and other tests over 96 weeks to s…

This study is observing patients with moderate-to-severe psoriasis who are switching from one injectable medication (ustekinumab) to another (guselkumab) as part of their regular doctor's care. Researchers will follow 200 patients for a year to see how well the new drug controls …

This study aims to understand how two newer immunotherapy drugs (teclistamab and talquetamab) work for patients with advanced multiple myeloma in real-world medical settings, not in controlled clinical trials. Researchers will look back at the medical records of about 900 patient…